Laner-Plamberger Sandra, Lener Thomas, Schmid Doris, Streif Doris A, Salzer Tina, Öller Michaela, Hauser-Kronberger Cornelia, Fischer Thorsten, Jacobs Volker R, Schallmoser Katharina, Gimona Mario, Rohde Eva
Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg, Austria.
Department of Blood Group Serology and Transfusion Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Lindhofstrasse 20-22, 5020, Salzburg, Austria.
J Transl Med. 2015 Nov 10;13:354. doi: 10.1186/s12967-015-0717-4.
Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL-supplemented medium to prevent clotting due to plasmatic coagulation factors. We therefore searched for an efficient and reproducible medium preparation method that avoids clot formation while omitting animal-derived heparin.
We established a protocol to deplete fibrinogen by clotting of pHPL in medium, subsequent mechanical hydrogel disruption and removal of the fibrin pellet. After primary culture, bone-marrow and umbilical cord derived MSCs were tested for surface markers by flow cytometry and for trilineage differentiation capacity. Proliferation and clonogenicity were analyzed for three passages.
The proposed clotting procedure reduced fibrinogen more than 1000-fold, while a volume recovery of 99.5 % was obtained. All MSC types were propagated in standard and fibrinogen-depleted medium. Flow cytometric phenotype profiles and adipogenic, osteogenic and chondrogenic differentiation potential in vitro were independent of MSC-source or medium type. Enhanced proliferation of MSCs was observed in the absence of fibrinogen but presence of heparin compared to standard medium. Interestingly, this proliferative response to heparin was not detected after an initial contact with fibrinogen during the isolation procedure.
Here, we present an efficient, reproducible and economical method in compliance to good manufacturing practice for the preparation of MSC media avoiding xenogenic components and suitable for clinical studies.
在临床研究中,混合人血小板裂解液(pHPL)是用于间充质干细胞(MSC)体外扩增的异种补充剂的有效替代品。目前,在添加pHPL的培养基中使用猪肝素以防止由于血浆凝血因子导致的凝血。因此,我们寻求一种高效且可重复的培养基制备方法,该方法可避免凝块形成,同时省略动物源性肝素。
我们建立了一种方案,通过在培养基中使pHPL凝血、随后机械破坏水凝胶并去除纤维蛋白沉淀来消耗纤维蛋白原。原代培养后,通过流式细胞术检测骨髓和脐带来源的MSC的表面标志物,并检测其三系分化能力。对三代细胞进行增殖和克隆形成分析。
所提出的凝血程序使纤维蛋白原减少了1000倍以上,同时体积回收率达到99.5%。所有类型的MSC均在标准培养基和无纤维蛋白原的培养基中增殖。流式细胞术表型谱以及体外成脂、成骨和软骨分化潜能与MSC来源或培养基类型无关。与标准培养基相比,在无纤维蛋白原但有肝素的情况下观察到MSC增殖增强。有趣的是,在分离过程中最初接触纤维蛋白原后,未检测到这种对肝素的增殖反应。
在此,我们提出了一种高效、可重复且经济的方法,符合良好生产规范,用于制备不含异种成分且适用于临床研究的MSC培养基。